CMPS

#1736
COMPASS Pathways Plc - American Depository Shares
13.0 6 USD
+9.56%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
13.06
13.06
Range Annuel
0.12
13.06
Changement quotidien
+9.56%
Changement Mensuel
+54.37%
Evolution sur 6 mois
+138.32%
Changement Annuel
+105.02%
Clôture Précédente
11.9 2
Open
13.0 6
Low
13.0 6
High
13.0 6
Volume
59
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 1.76 B
  • Employee 156
  • Founded 2016
  • CEO N/A
  • Website compasspathways.com
  • Headquarter United Kingdom
  • FIGI BBG00X0VY2N1
  • Industry Établissements de Soins Médicaux
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-2.24
ratio cours/chiffre d'affaires
185.88

COMPASS Pathways Plc - American Depository Shares

Compass Pathways, or COMPASS Pathways, is a British pharmaceutical company developing psychedelics as potential medicines. Its main drug candidate, psilocybin, is currently in phase 3 clinical trials for treatment-resistant depression. This candidate has received breakthrough therapy status from the U.S. Food and Drug Administration. It is the most advanced psychedelic drug candidate in development besides Lykos Therapeutics's midomafetamine. Compass Pathways is the largest company in the psychedelic medicine industry and, in 2020, was the first psychedelic medicine company to be listed on the NASDAQ. It has faced criticism for patenting psychedelic drugs and even certain psilocybin mushroom species. In October 2024, after the FDA rejected Lykos Therapeutics's MDMA for post-traumatic stress disorder New Drug Application, Compass Pathways said that it would lay off 30% of its workforce and narrow its research focus. Compass Pathways has entered partnerships with several independent psychedelic academic scientists, including Jason Wallach, Hamilton Morris, and Adam Halberstadt among others, to develop novel psychedelic drugs for potential medical use.

Nouvelles